Daxor
About: Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Employees: 750
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
7% more capital invested
Capital invested by funds: $757K [Q3] → $811K (+$54.7K) [Q4]
0.36% more ownership
Funds ownership: 1.8% [Q3] → 2.16% (+0.36%) [Q4]
0% more funds holding
Funds holding: 9 [Q3] → 9 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for DXR.
Financial journalist opinion
Based on 13 articles about DXR published over the past 30 days









